Xenon Pharmaceuticals Inc (NASDAQ:XENE) – Equities researchers at Jefferies Group issued their Q1 2018 EPS estimates for Xenon Pharmaceuticals in a research report issued to clients and investors on Thursday, according to Zacks Investment Research. Jefferies Group analyst M. Raycroft anticipates that the biopharmaceutical company will post earnings per share of ($0.49) for the quarter. Jefferies Group also issued estimates for Xenon Pharmaceuticals’ Q2 2018 earnings at ($0.51) EPS, Q3 2018 earnings at ($0.54) EPS, Q4 2018 earnings at $0.19 EPS, FY2018 earnings at ($1.34) EPS, FY2019 earnings at ($1.88) EPS, FY2020 earnings at ($1.76) EPS, FY2021 earnings at $1.64 EPS and FY2022 earnings at $2.11 EPS.
Xenon Pharmaceuticals (NASDAQ:XENE) last announced its earnings results on Wednesday, March 7th. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by ($0.34). The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $6.38 million. Xenon Pharmaceuticals had a negative return on equity of 65.72% and a negative net margin of 9,872.67%.
XENE has been the subject of several other reports. Zacks Investment Research raised Xenon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, February 28th. ValuEngine upgraded Xenon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, March 1st. Finally, Stifel Nicolaus boosted their price target on Xenon Pharmaceuticals from $7.00 to $9.00 and gave the stock a “buy” rating in a research report on Thursday, March 8th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company’s stock. Xenon Pharmaceuticals has an average rating of “Hold” and an average target price of $6.33.
XENE stock opened at $4.80 on Monday. The company has a current ratio of 10.98, a quick ratio of 10.99 and a debt-to-equity ratio of 0.17. Xenon Pharmaceuticals has a 52 week low of $2.10 and a 52 week high of $9.95.
Several institutional investors and hedge funds have recently modified their holdings of XENE. K2 Principal Fund L.P. increased its position in shares of Xenon Pharmaceuticals by 33.5% during the fourth quarter. K2 Principal Fund L.P. now owns 219,543 shares of the biopharmaceutical company’s stock worth $620,000 after purchasing an additional 55,033 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Xenon Pharmaceuticals by 59.2% during the fourth quarter. Renaissance Technologies LLC now owns 249,000 shares of the biopharmaceutical company’s stock worth $703,000 after purchasing an additional 92,600 shares in the last quarter. Finally, Sabby Management LLC increased its position in shares of Xenon Pharmaceuticals by 7.1% during the fourth quarter. Sabby Management LLC now owns 329,400 shares of the biopharmaceutical company’s stock worth $931,000 after purchasing an additional 21,800 shares in the last quarter. Hedge funds and other institutional investors own 50.87% of the company’s stock.
WARNING: This article was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2018/03/21/xenon-pharmaceuticals-inc-xene-forecasted-to-earn-q1-2018-earnings-of-0-49-per-share.html.
About Xenon Pharmaceuticals
Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD).
Get a free copy of the Zacks research report on Xenon Pharmaceuticals (XENE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.